Head of Urological Department
Prof. Francesco Montorsi MD FRCS is Professor and Chairman of the Department of Urology at Vita Salute San Raffaele University in Milan Italy. He is also Scientific Director of the San Raffaele Hospital Scientific Institute.
Prof Montorsi serves as Adjunct Secretary General of the European Association of Urology and Editor-in-Chief Emeritus of European Urology. Professor Montorsi’s major research interests have included several urological areas with a specific focus on pathophysiology, diagnosis and treatment of prostate cancer, urologic oncology, benign prostatic hyperplasia and sexual dysfunctions. As a widely published author, Professor Montorsi has written and coauthored more than 1,000 peer reviewed journal articles and several book chapters. At present Prof. Montorsi’s H-Index is 80 (12.2015). His articles have been published in many prestigious journals including The New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, British Medical Journal, European Heart Journal, Diabetes Care, Drugs, Cancer, Journal of Urology, British Journal of Urology International, Urology, The International Journal of Impotence Research, Surgery, The Journal of Sexual Medicine, International Journal of Cancer, European Journal of Cancer, Current Opinion of Urology and European Urology. Since 2006, he has been serving as Editor-in-Chief for European Urology. He is a reviewer for The New England Journal of Medicine, The Lancet, JAMA, The Journal of Urology and European Urology. In 1998 Professor Montorsi received the Matula Award, assigned yearly by the European Association of Urology to the Urologist < 40 years of age with the best scientific production. Since 2015 he is Adjunct General Secretary of European Association of Urology.
CLINICAL ACTIVITY (UO)
Number of procedures (UO)
KEY FACTS AND TECHNOLOGY (UO)
EDUCATIONAL AND RESEARCH ACTIVITY, IF (UO)
Professor Montorsi and his research team is daily involved in basic, clinical and translational projects. The Urological Research Institute (URI), which was founded about five years ago, is one of the first translational research department in the world in the field of urology. It holds unique opportunities to investigate a variety of aspects of urogenital disorders (epidemiological, genetic, molecular, cellular, physiological, pharmacological, clinical) of immediate relevance for the individual patient as well as health-care system of the community. An important aim of the research program is to produce an inspiring scientific environment that unifies clinical research and basic science in urology and urological pharmacology. Recruitment of young scientists and PhD students as well as national and international associations outside the Urological Research Institute is encouraged. URI developed translational projects in clinically relevant topics of uroncology and functional urology. Briefly, research focused on exploring safety and efficacy of mesenchymal stem cells carrying prodrug-converting genes in the treatment of prostate cancer. An immunocompetent mouse model was used. Tumor regression was achieved after delivery of therapeutic MSC cells, as evaluated by MRI. Efficacy of this therapeutic approach in targeting distant metastases is currently ongoing. Furthermore, the role the endocannabinoid system in the onset and progression of PCa has been studied. Research is also ongoing on functional urology preclinical models, which are targeted to elucidate the effects of both endocannabinoid system and transient potential receptors modulators in urinary and sexual functions and validate the use of cellular therapy for the treatment of erectile dysfunctions consequent to nerve damage by radical surgery. Besides translational projects, clinical research remains the core area of research in URI and San Raffaele.